SCHEMBL1640326

SCHEMBL1640326

O=C(NCc1ccccc1)c1cn(Cc2ccccc2)c(=O)cc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.58
EGLN3 Q9H6Z9 1/20 0.58
ALDH1A1 P00352 3/20 0.55
HPGD P15428 3/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
P2RX7 Q99572 1/20 0.52
BRD4 O60885 3/20 0.50
BRD2 P25440 1/20 0.50
BRD3 Q15059 1/20 0.50
BRDT Q58F21 1/20 0.50
PDE10A Q9Y233 1/20 0.48
KLKB1 P03952 1/20 0.48
KDM4E B2RXH2 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CNR2 P34972 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642209 0.93 EGLN1 (0.53) HSP90AA1EGLN3ALDH1A1HPGDLMNA
SCHEMBL1641375 0.90 HSP90AA1 (0.53) HSP90AA1EGLN3ALDH1A1HPGDLMNA
SCHEMBL1640573 0.88 BRD4 (0.65) ALDH1A1HPGDLMNAMAPTHTT
SCHEMBL1642389 0.86 EGLN1 (0.48) EGLN3ALDH1A1HTTSMN1; SMN2BRD4
SCHEMBL1641774 0.86 ALDH1A1 (0.53) ALDH1A1HPGDLMNAMAPTHTT
SCHEMBL1642053 0.84 MAPT (0.59) ALDH1A1HPGDLMNAMAPTHTT
SCHEMBL1641629 0.84 BRD4 (0.59) ALDH1A1HPGDKMT2AMEN1P2RX7
SCHEMBL1640352 0.83 LMNA (0.55) ALDH1A1LMNAMAPTKMT2AMEN1
SCHEMBL1641827 0.82 BRD4 (0.57) MAPTKMT2AMEN1BRD4BRD2
SCHEMBL1641829 0.81 TAS1R3 (0.57) ALDH1A1HPGDLMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 HSP90AA1 789/4885EGLN3 3/4885ALDH1A1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.